Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10493459" target="_blank" >RIV/00179906:_____/25:10493459 - isvavai.cz</a>
Alternative codes found
RIV/60162694:G44__/26:00564320 RIV/00843989:_____/25:E0111776 RIV/00216224:14110/25:00141734 RIV/61988987:17110/25:A2603DO9 and 5 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=svoq~BeJgo" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=svoq~BeJgo</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2024.287062" target="_blank" >10.3324/haematol.2024.287062</a>

Result language
angličtina
Original language name
Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia
Original language description
Blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, is effective in treating relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL), though most patients relapse despite achieving measurable residual disease (MRD) negativity. In the MRD setting, blinatumomab induced MRD negativity (MRDneg) in 78% of patients, with 85% achieving MRD <10-4. Patients treated in their first complete remission (CR) showed better outcomes than those treated in later remissions. These findings support integrating blinatumomab into first-line polychemotherapy, as early MRD clearance significantly improves survival and reduces relapse risks.3 The open-label phase 2 Blina-CELL trial evaluated the effects of one cycle of blinatumomab following 7-day pretreatment with dexamethasone and chemotherapy in adult patients with Ph-negative B-ALL. Conducted at four centers in the Czech Republic, the trial assessed MRDneg rates after a short Pre- Induction, one cycle of blinatumomab and one cycle of high-dose chemotherapy. The study was approved by central and institutional review boards and registered on clinicaltrials.gov (NCT04554485). All participants provided informed consent in accordance with the Declaration of Helsinki.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)